SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflix is a top trending stock following its earnings report, which, despite beating estimates, has been overshadowed by concerns regarding the Warner Bros Discovery acquisition. The community is sharply divided, with bulls viewing the current dip as an oversold opportunity for long-term content expansion, while bears cite the deal's cost, debt implications, and paused share buybacks as reasons for further downside. This strategic move and its perceived impact on future margins are driving intense discussion and significant price action.

Brand Engagement Network, Inc. engages in the provision of conversational artificial intelligence assistants with the purpose of transforming engagement and analytics for businesses through security-focused, multimodal communication and human-like artificial intelligence assistants. The firm is also involved in delivering highly personalized, multi-modal artificial intelligence engagement with a focus on industries where there is a massive workforce gap and an opportunity to transform how consumers engage with networks, providers, and brands. The company is founded on March 14, 2024 and is headquartered in Jackson, WY.

Brand Engagement Network Inc

Brand Engagement Network ($BNAI) is experiencing significant market attention following news of a strategic AI licensing partnership in Africa, including a pilot program with Nelson Mandela University. This development, combined with discussions around a reportedly thin float and high short interest, is driving substantial pre-market volatility and community speculation about a potential short squeeze. Traders are actively monitoring for sustained momentum, positioning BNAI as a key focus within the AI sector narrative.

PAVmed, Inc. is a multi-product life sciences company, which engages in the innovation, development, acquisition, and commercialization of products that target unmet medical needs with large addressable market opportunities. Its products include Lucid Diagnostics and Veris Health. The company was founded by Lishan Aklog and Brian J. deGuzman on June 26, 2014 and is headquartered in New York, NY.

PAVmed Inc

PAVmed is currently a top trending stock after its subsidiary, Lucid Diagnostics, announced a major contract with the U.S. Department of Veterans Affairs for its EsoGuard esophageal DNA test. This significant development has ignited investor excitement, with many discussing the potential for substantial price movement given the company's low float, even as some longer-term holders express caution regarding historical performance.

Alpha Tau Medical Ltd. is a clinical-stage oncology therapeutics company, which focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy for the treatment of cancer. The firm is involved in the clinical trials at cancer centers with indications that include skin cancer, oral cavity cancer, breast cancer, and pancreatic cancer. The company was founded by Uzi Sofer, Yona Keisari, and Itzhak Kelson in November 2015 and is headquartered in Jerusalem, Israel.

Alpha Tau Medical Ltd

ALPHA TAU MEDICAL LTD

Alpha Tau Medical (DRTS) is trending with immense community excitement, primarily driven by the high anticipation of potential PMDA Japan approval for its Alpha DaRT therapy, following compelling pancreatic cancer data. Investors are increasingly bullish, viewing recent strong clinical updates and growing institutional interest as key catalysts for this innovative oncology technology, which many believe is poised for significant recognition.

SPDR Gold Trust - SPDR Gold Shares

SPDR Gold Shares ETF

SPDR Gold Shares ETF (GLD) is experiencing a parabolic rally to new record highs, driven by escalating global trade tensions and broad geopolitical uncertainty. The community is actively discussing gold's role as a safe haven amidst concerns over sovereign debt, potential currency debasement, and central bank diversification, fueling significant short-covering and strong bullish momentum.

ProShares Trust - ProShares UltraShort Bloomberg Natural Gas -2x Shares

ProShares UltraShort Bloomberg Natural Gas

KOLD is experiencing significant volatility and declines as natural gas futures surge dramatically, driven by widespread "Arctic Blast" weather forecasts across the US. This rapid price action is causing extreme pressure for many traders, leading to discussions of a "widowmaker" market as some cautiously "buy the dip" on KOLD while others are caught in the squeeze.

Hycroft Mining Holding Corp. engages in the exploration, mining, and development of gold and silver properties. The company was founded on August 28, 2017 and is headquartered in Winnemucca, NV.

Hycroft Mining Holding Corporation - Ordinary Shares - Class A

Hycroft Mining Holding Corp

Hycroft Mining is seeing a significant surge in conversation, driven by recent reports of high-grade silver and gold drill results and continued accumulation by mining billionaire Eric Sprott. The community is intensely divided, with many anticipating a substantial short squeeze and linking its prospects to a booming precious metals market, while others caution about potential dilution and the company's lack of current production.

Corvus Pharmaceuticals, Inc. engages in the development of immune modulator product candidates with the potential to treat solid cancers, T-cell lymphomas, autoimmune diseases, and infectious diseases. Its product pipeline includes B Cell Activator and Anti-CD73, Adenosine Production Inhibitor Anti-CD73, ITK Inhibitor, A2AR Inhibitor, Anti-CXCR2, and A2BR Inhibitor. The company was founded by Richard A. Miller, Peter A. Thompson, Joseph J. Buggy, and Erik Verner on January 27, 2014 and is headquartered in South San Francisco, CA.

Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals is trending due to overwhelmingly positive Phase 1 clinical trial results for its atopic dermatitis drug, soquelitinib, demonstrating strong efficacy and a favorable safety profile even in treatment-resistant patients. This promising early data has ignited bullish sentiment about its blockbuster potential and possible short squeeze, despite community concerns surrounding a recently announced public offering to fund future trials.

Memecoin on Cronos launched by the Cro Crow community

crow with knife

Crow With Knife ($CAW) is currently a trending multi-chain meme coin, garnering significant attention as its community emphasizes its deflationary mechanics and organic cult-like growth across Solana, Cronos, and Base. Enthusiasts are actively discussing its potential to bring substantial volume to various chains and are anticipating further developments like staking opportunities, positioning it as a formidable player in the meme coin sector.

SSgA Active Trust - SPDR S&P 500 ETF Trust

SPY is trending due to immediate market uncertainty surrounding an anticipated speech by Donald Trump at Davos, sparking community debate over potential tariffs and geopolitical tensions, particularly regarding Greenland. Sentiment is split, with some traders concerned about rising Japanese bond yields and broader market weakness, while others expect a rebound, highlighting underlying economic resilience and a potential rotation into small-cap and value stocks.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>According to a report, AIG’s competitor, Chubb, approached the firm with an informal offer to acquire it; however, both Chubb and AIG denied the reports.</li><li>Citi maintained its ‘Neutral’ rating on AIG and assigned an $85 price target.</li><li>Piper Sandler raised its price target on the stock to $95 from $88 and maintained an ‘Overweight’ rating.</li></ul>American International Group (<a href="https://stocktwits.com/symbol/AIG">AIG</a>) stock drew investor attention on Monday after Citi analysts noted that merging with another large insurer would not benefit AIG.According to TheFly, Citi analysts wrote in a research note that they expect American International Group (AIG) to continue acquiring more firms rather than being acquired. Citi believes integration and revenue dyssynergies would likely overwhelm any potential cost savings from a large-scale transaction. The firm maintained a ‘Neutral’ rating on the shares, with an $85 price target.Earlier in the month, an Insurance Insider US <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.insuranceinsiderus.com/article/2fpahsm5la3on7eapsfsw/all-topics/m-a/chubb-made-informal-takeover-approach-for-aig?zephr_sso_ott=LTYHsi">report</a> indicated that Chubb had approached AIG with an informal acquisition offer. However, both firms have reportedly <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.insurancenews.com.au/international/aig-not-for-sale-amid-reports-of-rival-s-interest">denied</a> the same, according to Insurance News.&nbsp;In another note, Piper Sandler raised its price target on AIG to $95 from $88 and maintained an Overweight rating. The firm expects favorable weather to mean most insurers will report strong or even stronger-than-expected results, but pricing commentary will likely be more pessimistic.<h2 class="st-heading-2">Expansion Amidst Streamlining Operations</h2>AIG’s CEO, Peter Zaffino, has been streamlining its operations since taking the reins in 2021 by selling its global personal travel business, and continues to make acquisitions and investments to make AIG into a more capital-aligned company.AIG recently announced it will invest around $5 billion in specialty insurer Convex and asset manager Onex Corporation. As part of the deal, AIG acquired a 35% stake in Convex for $2.1 billion. It also said it will acquire a 9.9% ownership stake in asset manager Onex for about $646 million and will also invest up to $2 billion in its investment funds.AIG also <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://investors.everestglobal.com/news/news-details/2025/Everest-Announces-Agreement-to-Sell-Retail-Commercial-Insurance-Renewal-Rights-to-AIG/default.aspx">acquired</a> renewal rights to Everest Group’s global retail insurance portfolio for about $2 billion, which will allow AIG to grow its general insurance arm by incorporating Everest’s existing customers.<h2 class="st-heading-2">How Did Stoctwits Users React?</h2>Retail sentiment around AIG trended in “bearish” territory amid “high” message volumes.<figure class="image"><img style="aspect-ratio:633/74;" src="https://news.stocktwits-cdn.com/AIG_PNG_22be5e3e02.webp" alt="Retail sentiment around AIG trended in “bearish” territory amid “high” message volumes" width="633" height="74"></figure>Shares of AIG have surged over 10% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com. &nbsp;

The AIG (American International Group) logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Why Does Citi Believe AIG Is More Likely To ‘Acquire’ Than Be Acquired?

Citi analysts believe integration and revenue dyssynergies would likely overwhelm any potential cost savings from a large-scale transaction.

Equity

Citi analysts believe integration and revenue dyssynergies would likely overwhelm any potential cost savings from a large-scale transaction.


Boston Scientific Corporation (BSX) said on Friday that it has entered into a definitive agreement to acquire privately held medical technology company Nalu Medical for an upfront cash payment of approximately $533 million for equity not currently owned by the company.Nalu is developing minimally invasive solutions for patients with chronic pain, and Boston Scientific has been a strategic investor in the company since 2017.The transaction is <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.prnewswire.com/news-releases/boston-scientific-announces-agreement-to-acquire-nalu-medical-inc-302587495.html">expected</a> to be completed in the first half of 2026, subject to the satisfaction of customary closing conditions. The transaction is not expected to impact Boston Scientific’s adjusted earnings per share (EPS) in 2026. However, the company expects it to be slightly accretive to adjusted EPS in 2027 and increasingly accretive thereafter.BSX shares traded down 1% in the pre-market session at the time of writing. On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/BSX">BSX stock</a> stayed within the ‘bearish’ territory over the past 24 hours, while message volume stayed at ‘low’ levels.The acquisition is intended to expand the neuromodulation offerings for people living with chronic pain, Boston Scientific said."Adding the highly differentiated Nalu Medical technology complements our existing therapies—including spinal cord stimulation, basivertebral nerve ablation and radiofrequency ablation—enabling us to deliver advanced pain relief options to a wider variety of patient populations," President Jim Cassidy said.Nalu is expected to generate sales of more than $60 million in 2025 and to deliver year-over-year growth of over 25% in 2026.BSX stock is up by 9% this year and by about 13% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/cryptocurrency/bitcoin-falls-below-105-000-pulling-mstr-stock-lower-xrp-and-solana-drop/ch6sexmR383">Bitcoin Falls Below $105,000, Pulling MSTR Lower – XRP And Solana Drop Amid Banking Jitters</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

A general view of a Boston Scientific advertisement during a women's college lacrosse game between the Notre Dame Fighting Irish and the Boston College Eagles on March 16, 2024. (Photo by Erica Denhoff/Icon Sportswire via Getty Images)

Boston Scientific To Acquire Privately-Held Pain Solutions Developer Nalu Medical For About $533M

Nalu Medical is developing minimally invasive solutions for patients with chronic pain, and Boston Scientific has been a strategic investor in the company since 2017.

Three varieties of McCormick spices in plastic table shaker containers. Salt free all purpose, garlic and herb and Perfect Pinch salt free garlic and herb. Variety of prepared and mixed Seasonings to add to any food dish.

McCormick CEO Flags Rising Prices On Global Trade Pressures: ‘Expect To Offset Rising Commodity Costs And Tariffs As Much As We Can’

McCormick now expects annual adjusted profit to be between $3 and $3.05 per share, compared with its previous estimate of $3.03 to $3.08 per share.

Med-tech company Medtronic (MDT) announced on Tuesday that its board of directors has appointed industry veterans John Groetelaars and Bill Jellison as independent directors, effective immediately, after Elliott Investment Management added a substantial stake in the firm.The company also announced the formation of two special committees. Of this, one will be responsible for guiding the evaluation and execution of growth-accretive tuck-in mergers and acquisitions, organic research and development investments, and potential divestitures.The other committee will align governance with the company's initiatives to optimize operational performance, deliver margin expansion, and drive sustained earnings acceleration, the company said.CEO Geoff Martha will serve as Chair of both of the newly formed committees, and both the newly appointed directors will serve on one or both of the committees. Groetelaars and Jellison will further be nominated to stand for election to the board at Medtronic's 2025 annual general meeting of shareholders, it <a target="_blank" rel="noopener noreferrer nofollow" href="https://news.medtronic.com/2025-08-19-Medtronic-announces-Board-appointments-and-shareholder-value-creation-initiatives-to-advance-strategic-priorities">said</a>.The company said that the move followed dialogue with Elliott Investment Management L.P., which is now one of the largest investors in the company. Elliott Partner Marc Steinberg stated that the decision to become one of the largest investors in Medtronic was driven by the conviction that the company is entering a new chapter of value creation.“We believe Medtronic's recent innovations in some of the medical technology sector's most attractive markets have positioned the company for an inflection in organic growth… Today's announcements – including the addition of new directors with deep medical technology experience and the formation of two focused Board committees – are the right steps towards realizing Medtronic's potential,” Steinberg said.The Wall Street Journal reported the board appointments earlier today. On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/MDT">MDT</a> jumped from ‘bullish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘normal’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:627/62;" src="https://news.stocktwits-cdn.com/Screenshot_2025_08_19_at_7_52_05_AM_png_5d5cc8d38a.webp" alt="MDT's Sentiment Meter and Message Volume as of 7:50 a.m. ET on Aug. 19, 2025 | Source: Stocktwits" width="627" height="62"><figcaption>MDT's Sentiment Meter and Message Volume as of 7:50 a.m. ET on Aug. 19, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user believes the company’s long-term value looks solid, if it can maintain steady revenue growth and keep innovating in key product lines.<stembedurl>https://stocktwits.com/JasonInsightMarkets/message/625725317</stembedurl>On Tuesday, the company <a target="_blank" rel="noopener noreferrer nofollow" href="https://news.medtronic.com/2025-08-19-Medtronic-reports-first-quarter-fiscal-2026-financial-results">reported</a> earnings for the first quarter of fiscal year 2026 (FY26), which ended July 25, and raised its FY26 earnings guidance. For FY26, the company continues to expect organic revenue growth of approximately 5%. It also raised its FY26 diluted and adjusted earnings per share guidance to the new range of $5.60 to $5.66 versus the prior range of $5.50 to $5.60.For the first quarter, the firm reported revenue of $8.578 billion, exceeding a Wall Street estimate of $8.371 billion. The growth was spurred by growth across the company’s cardiovascular, neuroscience, medical surgical, and diabetes business portfolios.Adjusted and diluted earnings per share in the quarter came in at $1.26, above an estimated $1.23.MDT stock is up by 16% this year and by about 9% over the past 12 months.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/nvidia-readying-new-blackwell-based-b30-a-chip-for-china-as-us-tensions-flare-report/chsgO5iRdg9">Nvidia Readying New Blackwell-Based B30A Chip For China As US Tensions Flare: Report</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

The Medtronic logo is displayed on a smartphone screen in front of a stock chart showcasing Medtronic's financial performance. (Photo by Cheng Xin/Getty Images)

Medtronic Appoints New Directors After Elliott Becomes Major Investor: Company Hikes FY26 Guidance After Q1 Beat

Elliott Partner Marc Steinberg stated that the decision to become one of the largest investors in Medtronic was driven by the conviction that the company is entering a new chapter of value creation. 

Analysts are optimistic about Medtronic (MDT) after the Centers for Medicare and Medicaid Services (CMS) proposed to cover renal denervation for uncontrolled hypertension.CMS on Thursday posted its proposed decision memo, stating that it proposes to cover radiofrequency renal denervation and ultrasound renal denervation for uncontrolled hypertension. The agency is now seeking comments on its proposed decision, and a final decision is expected by October 8.Renal denervation (RDN) is a new technology that uses catheters placed into the renal (kidney) arteries to ablate, or destroy, the renal sympathetic nerves to reduce blood pressure. RDN is intended to complement medications and lifestyle changes in patients with uncontrolled hypertension.Hypertension can lead to serious problems such as heart attack and stroke, the agency noted.Medtronic, the medical technology provider, has an RDN system called Symplicity Spyral, which was granted FDA premarket approval in November 2023. The system disrupts the overactive sympathetic signaling between the kidneys and brain to reduce blood pressure.<a href="https://stocktwits.com/symbol/MDT">MDT shares </a>were trading 1% higher at the time of writing.&nbsp;Several analysts reacted to the news:<ul style="list-style-type:square;"><li>Stifel maintains a ‘Hold’ rating and $87 price target on Medtronic shares. The Centers for Medicare &amp; Medicaid Services' initial proposal for renal denervation reimbursement "seems positive," the firm noted.</li><li>JPMorgan, meanwhile, keeps a ‘Neutral’ rating on Medtronic. JPMorgan told investors in a research note that there is no arguing that a broad national coverage decision for renal denervation is a win for Medtronic. This will enable the company to begin targeting the potentially multi-billion-dollar opportunity once the final rule is released in October, according to the analyst. However, JPMorgan believes it will "take some time to get there" as the company will need to educate primary care physicians and general cardiologists.</li><li>BTIG analyst Ryan Zimmerman keeps a ‘Neutral’ rating on Medtronic. BTIG said that while the news was expected, it is still a win for Medtronic. BTIG believes the decision opens up Medtronic to a "massive" potential patient pool.</li></ul>&nbsp;On Stocktwits, retail sentiment around Medtronic stayed within ‘neutral’ territory over the past 24 hours while message volume stayed at ‘normal’ levels.<figure class="image"><img style="aspect-ratio:625/62;" src="https://news.stocktwits-cdn.com/Screenshot_2025_07_11_at_1_28_21_PM_png_9314bf702a.webp" alt="MDT's Sentiment Meter and Message Volume as of 1:30 p.m. ET on July 11, 2025 | Source: Stocktwits" width="625" height="62"><figcaption>MDT's Sentiment Meter and Message Volume as of 1:30 p.m. ET on July 11, 2025 | Source: Stocktwits</figcaption></figure>MDT stock is up by nearly 13% this year and by over 15% over the past 12 months.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/cel-sci-to-sign-partnership-with-saudi-arabian-pharma-company-for-cancer-drug/ch8c1PLR5ZC">CEL-SCI Stock Soars On Imminent Partnership With Saudi Arabian Pharma Company For Cancer Drug: Retail’s Thrilled</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

CMS’s Initial Proposal To Cover Renal Denervation A Win For Medtronic, Says Analysts

CMS is now seeking comments on its proposed decision, and a final decision is expected by October 8.

Health technology company Medtronic plc (MDT) on Tuesday announced the appointment of Chad Spooner as CFO of MiniMed.The appointment comes ahead of MiniMed’s separation from Medtronic as a standalone, public company. MDT shares are trading 1% higher at the time of writing.Medtronic announced its <a href="https://stocktwits.com/news-articles/markets/equity/medtronic-announes-split-of-diabetes-business/ch0ec0dRbYg">intent to split</a> its Diabetes business into a standalone company in May. The move, it said, will create a more focused Medtronic, with a more simplified portfolio including cardiovascular, neuroscience, and medical-surgical.The company also noted that the separation is expected to be accretive to Medtronic’s earnings and operating margin.<a href="https://stocktwits.com/symbol/MDT">Medtronic</a> expects the separation to be completed within 18 months of the initial announcement. The company is eyeing an initial public offering (IPO) and subsequent split-off.Que Dallara will be the CEO of the new diabetes company, named MiniMed, which is expected to have over 8,000 employees. Dallara is currently the President of Medtronic Diabetes.Spooner’s appointment will be effective July 14, and he will be responsible for overseeing the Finance function for Medtronic Diabetes and supporting initiatives.He was most recently CFO at BIC, a publicly traded global consumer goods company. Dallara also held leadership roles across healthcare, consumer, and industrial sectors, including at Raffaela Apparel Group, Slingshot Health, and Tenex Capital Management.Medtronic’s diabetes portfolio reported revenue of $2.76 billion in fiscal year 2025 (FY25), marking a growth of 10.7% year-on-year (YoY) and representing 8% of Medtronic’s total revenue in the period.On Stocktwits, retail sentiment around Medtronic is trending in the ‘neutral’ territory over the past 24 hours, coupled with ‘high’ message volume.<figure class="image"><img style="aspect-ratio:1378/122;" src="https://news.stocktwits-cdn.com/Screenshot_2025_07_08_at_12_41_52_PM_png_5beb980fab.webp" alt="MDT's Sentiment Meter and Message Volume as of 12:40 p.m. ET on July 8, 2025 | Source: Stocktwits" width="1378" height="122"><figcaption>MDT's Sentiment Meter and Message Volume as of 12:40 p.m. ET on July 8, 2025 | Source: Stocktwits</figcaption></figure>MDT stock is up by 11% this year and by about 15% over the past 12 months.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/novo-nordisk-seeks-approval-for-higher-wegovy-dose-in-europe/chFvDEAR5Wj">Novo Nordisk Seeks Approval For Higher Wegovy Dose In Europe</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Medtronic Names CFO For New Diabetes Company Ahead Of Intended Spin-Off

Chad Spooner’s appointment will be effective July 14, and he will be responsible for overseeing the Finance function for Medtronic Diabetes and supporting initiatives.

Up 10% or more

0% to up 9%

Down 1% to 9%

Down 10% or more

The S&P 500 enters 2026 after a strong run. What kind of return do you expect this year?

How will the S&amp;P 500 perform in 2026?

XRLV
Invesco S&P 500 ex-Rate Sensitive Low Volatility ETF

Feed

News

Sentiment

Fundamentals

Info

Poll

Latest XRLV News

XRLVInvesco S&P 500 ex-Rate Sensitive Low Volatility ETF